Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1348189 | 0.87 | CYP3A4 (0.57) | CYP3A4PDPK1GRIN1GRIN2BEP300 | |
| SCHEMBL1542738 | 0.83 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL12849878 | 0.81 | CYP3A4 (0.55) | CYP3A4HSP90AA1HSP90AB1PDPK1IKBKB | |
| SCHEMBL1542456 | 0.73 | CYP3A4 (0.46) | CYP3A4CTSSHSP90AA1HSP90AB1PDPK1 | |
| SCHEMBL1542589 | 0.73 | CYP3A4 (0.47) | CYP3A4CTSSHSP90AA1HSP90AB1 | |
| SCHEMBL1542324 | 0.73 | CYP3A4 (0.62) | CYP3A4EP300 | |
| SCHEMBL1542367 | 0.73 | CYP3A4 (0.62) | CYP3A4EP300 | |
| SCHEMBL1542619 | 0.73 | CYP3A4 (0.67) | CYP3A4EP300KDM4ELMNA | |
| SCHEMBL1348834 | 0.71 | CYP3A4 (0.57) | CYP3A4HSP90AA1PDPK1IKBKBCHUK | |
| SCHEMBL1542382 | 0.71 | CYP3A4 (0.59) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063072-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | claimed |
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LI JIM | 2011-03-24 | — | — | US | claimed |
| US-8063072-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LI JIM | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885CTSS 1131/4885HSP90AA1 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.